Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1 to 25 of 511

TitleReference numberPublishedLast updated
Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal)TA1144
Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessmentHTG776
Fetal monitoring in labourNG229
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and overTA1140
Pegzilarginase for treating arginase-1 deficiency in people 2 years and overHST35
Hypertension in adults: diagnosis and managementNG136
Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)TA1137
Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal)TA1135
Type 2 diabetes in adults: managementNG28
Type 2 diabetes in adultsQS209
Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal)TA1132
Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal)TA1124
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)TA972
Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)TA1123
Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal)TA1118
VA ECMO for postcardiotomy cardiogenic shock in adultsHTG762
Child maltreatment: when to suspect maltreatment in under 18sCG89
Suspected sepsis in pregnant or recently pregnant people: recognition, diagnosis and early managementNG255
Suspected sepsis in people aged 16 or over: recognition, assessment and early managementNG253
Suspected sepsis in under 16s: recognition, diagnosis and early managementNG254
Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal)TA1111
Suspected sepsis in over 16sQS213
Cabotegravir for preventing HIV-1 in adults and young peopleTA1106
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)TA1104
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)TA1105

Results per page

  1. 10
  2. 25
  3. 50
  4. All